Higher Risks of Gastrointestinal Effects in Diabetic Patients In October 2023, The Journal of the American Medical Association(JAMA), examined adverse events in patients with diabetes associated with GLP-1 RA in a research letter called Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss where it concluded that studies have found increased risks of gastrointestinal adverse events, such as biliary disease, pancreatitis, bowel obstruction, and gastroparesis
Why PHRC versus anyone else
In certain cases, patients may present with nonspecific symptoms like fatigue, unexplained weight loss, or discomfort in the upper right abdomen, particularly in those with more advanced disease or NASH
In DMM-induced OA models, SM04690@ApoF reduces OARSI scores by 40%, preserves cartilage structure, and promotes proteoglycan deposition
While compounded GLP-1 medications may use the same active pharmaceutical ingredients found in branded drugs, the FDA does not review compounded formulations for safety, efficacy, or manufacturing quality in their final form
Methylene Blue Jfa 41